
Please try another search
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
Name | Age | Since | Title |
---|---|---|---|
Tomasz Piec | 52 | 2020 | Vice Chairman of the Supervisory Board |
Bart N. Lambrecht | - | - | Member of Scientific Advisory Board |
Paul Van Der Horst | - | 2022 | Independent Chairman of the Supervisory Board |
Pawel Trawkowski | - | 2022 | Independent Member of the Supervisory Board |
Douglas W.P. Hay | - | - | Member of Scientific Advisory Board |
Luke O’Neill | 60 | - | Member of Scientific Advisory Board |
Nancy Van Osselaer | - | 2021 | Independent Member of the Supervisory Board |
Agnieszka Motyl | - | 2023 | Member of the Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review